Biological: GB261
Phase 1Small molecule
Biological: GB261 is one of 33 small molecule programs targeting Systemic Sclerosis. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
32
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
39 competitors in Systemic Sclerosis
#DrugCompanyPhaseTrials
1Tracleer
Johnson & JohnsonApproved
Olumiant
Eli LillyApproved
IC-Green
PProvepharm SAS
Approved
Flagyl
DDePuy Orthopaedics
Approved
Rituxan
RochePhase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Mesnex
BBaxter Healthcare Corporation
Phase 3
UPLIZNA
HHorizon Therapeutics Ireland DAC
Phase 3
Cellcept
RochePhase 2
Rezzayo
RochePhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Biological: GB261. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- RRuijin Hospital